Renal Impairment

Nephrology·MeSH: Renal Insufficiency

Prevalence

0.1 / 100K

11 drugs in development·8 companies·16 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
fosinopril	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(3)

Drug	Company
100 mg resmetirom	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
incb123667	Incyte Corp. (INCY)
MK-8527	Merck & Co., Inc. (MRK)

Phase 2(4)

Phase 1(3)

Drug	Company
EDG-7500	Edgewise Therapeutics, Inc. (EWTX)
LY3537031	ELI LILLY & Co (LLY)
Opemalirsen	ASTRAZENECA PLC (AZN)

BioSniper tracks 11 drugs in development for Renal Impairment across 8 companies.

There are 16 clinical trials targeting Renal Impairment tracked by BioSniper.

The estimated prevalence of Renal Impairment is approximately 0.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.